New Technologies for Influenza Vaccines
Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vac...
Main Authors: | Steven Rockman, Karen L. Laurie, Simone Parkes, Adam Wheatley, Ian G. Barr |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | Microorganisms |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-2607/8/11/1745 |
Similar Items
-
Next Generation Influenza Vaccines: Looking into the Crystal Ball
by: Carlos Alberto Guzmán
Published: (2020-08-01) -
Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics
by: Olivia A. Vogel, et al.
Published: (2020-02-01) -
Egg-Independent Influenza Vaccines and Vaccine Candidates
by: Ilaria Manini, et al.
Published: (2017-07-01) -
Pandemic Influenza Vaccines: What did We Learn from the 2009 Pandemic and are We Better Prepared Now?
by: Steven Rockman, et al.
Published: (2020-05-01) -
A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade
by: Brigette N. Corder, et al.
Published: (2020-10-01)